Business Wire

Greek National Organization of Medicines Approves First Antimicrobial Formula for Residual Surface Protection Against SARS-CoV-2 (COVID-19 Virus) for up to 90 Days


ViaClean Technologies, LLC, a Philadelphia-based biotech company, jointly with its distributor and business development partner, Bizos Cavallo Enterprises LLC of Dallas, TX, and their partner, V-Clean Technologies S.A. of Athens, Greece, jointly announced the country of Greece's approval for the use of BIOPROTECT™ RTU on porous and non-porous surfaces in the fight against SARS-CoV-2. Greece has recognized BIOPROTECTTM RTU as inhibiting the growth of harmful bacteria and viruses, including SARS-CoV-2 (COVID virus), on surfaces for up to 90 days.

Having accepted and recognized the antimicrobial surface efficacy of BIOPROTECT™ RTU, Greece's National Organization of Medicines (ΕΟΦ) has approved the unrestricted consumer use of BIOPROTECT™ RTU to inhibit the growth of SARS-CoV-2 and other harmful viruses, bacteria, mold, and mildew, on treated surfaces. This innovative technology has proven to be effective for up to 90 days and has been applied in various public and private environments in Greece, including medical facilities, mass transit, education, commercial facilities, and more.

"ViaClean has been committed to supporting the reopening of Europe throughout the past year, hoping to instill a sense of normality as people navigate these unprecedented times," said ViaClean President and CEO, Greg Tipsord. "With Greece's adoption of BIOPROTECTTM RTU antimicrobial surface protectant, which inhibits the growth of SARS-CoV-2 and other harmful viruses and bacteria on surfaces, we believe Greece will benefit from this proven technology and strengthen their commitment to reach pre-pandemic levels of normalcy for their citizens. We've delivered an effective antimicrobial surface protectant solution that supports our mission of continued research, innovation, and dedication on a global scale."

"At V-Clean Technologies S.A., we have further cemented our commitment to Greece and the ongoing safety of our fellow citizens and visitors through our commitment to bringing innovative, patented technologies to our country to reduce the presence of bacteria, germs, fungi, algae, and other problematic micro-organisms including SARS CoV-2” said Panos Sofianos, President of V-Clean. “We thank the Greek government, and specifically the Ministry of Health and the National Organisation for Medicines (ΕΟΦ), our joint-venture distribution partner, Bizos Cavallo Enterprises and of course, ViaClean Technologies, for their rigor, diligence, and support throughout this process."

In Greece and in other European Member States, where regulatory approvals are pending, the unique non-leaching and non-volatile BIOPROTECTTM RTU formula has proven to be effective at killing harmful microbes and reducing odors for up to 90 days on various surfaces. "We are fortunate and thrilled to have partnered with both V-Clean Technologies and ViaClean Technologies by facilitating the approval process and distribution of BIOPROTECTTM RTU antimicrobial surface protectant for Greece," said Elvin Thibodeaux, Managing Partner of Bizos Cavallo Enterprises. "Our continued efforts will supply this innovative technology exclusively to additional markets, including the European Union and Balkan Peninsula, Russia and more, that are pursuing dynamic relief from the effects of the pandemic over the past 18 months."

In the United States, ViaClean markets the BIOPROTECTUs™ System, which uses patented, registered technologies: SmartTouch®, a List N disinfectant, to disinfect surfaces against viruses, bacteria, and germs, and BIOPROTECT™ RTU antimicrobial surface protectant, to keep surfaces free of odor- and stain-causing bacteria, fungi (mold and mildew), and algae between cleanings, for up to 90 days (3 months). In the United States, however, BIOPROTECT™ RTU is not currently approved or available for use against the SARS-CoV‑2 virus, other viruses, harmful bacteria, or any other harmful microorganisms.

Additional products offered from ViaClean and Bizos Cavallo in the United States, and pending approval in Greece, include the registered BIOPROTECT™ 500 concentrate, registered BIOPROTECTTM D disinfectant, and registered BIOPROTECT™ Hydrating Hand Sanitizer. For more information on ViaClean Technologies and The BIOPROTECTUs™ System, please visit For information on the aforementioned markets or sales with Bizos Cavallo Enterprises, visit

About ViaClean Technologies. LLC

ViaClean Technologies LLC is a biotech company that develops, manufactures, and markets groundbreaking, innovative antimicrobial solutions using environmentally responsible manufacturing processes. ViaClean Technologies' pioneering and proprietary technologies, products, and services provide disinfectants, antimicrobial protectants, and hand sanitizers for commercial and consumer use. ViaClean Technologies' primary mission is to market these advanced antimicrobial formulations to critical industries, manufacturing the registered formulations using environmentally responsible processes. For more information, visit the ViaClean website (

About V-Clean Technologies, S.A.

V-Clean Technologies S.A. is a biotechnology firm based in Athens, Greece that is focused on developing and marketing cutting edge technologies, products and services to meet the challenges and opportunities in Europe, Russia and the Middle East. In conjunction with our pharmaceutical affiliates and partners we strive for innovative and environmentally responsible solutions in an ever-changing marketplace. Having created a strong and sustainable network of strategic partners throughout these regions, we are able to be proactive and effective in providing services ranging from manufacturing, sourcing, logistics and regulatory advisory. For more information about V-Clean Technologies S.A. please visit our website (

About Bizos Cavallo Enterprises, LLC

Bizos Cavallo Enterprises, LLC is a strategic consulting and operations firm focused on emerging bioscience innovations for public health, strategic alliances, and global investment resources based in Dallas, TX, with offices in New Orleans, LA, and Winston-Salem, NC. In addition, Bizos Cavallo owns the subsidiary, BP&D International, LLC, a global leader in the procurement and the export of premium cultural commodities, including bulk grains, animal proteins, and their respective derivatives. Founded in 2017, Bizos Cavallo's network includes partners and a host of strategic alliances in the United States, Greece, China, South Korea, Japan, Singapore, Dubai, France, Brazil, the West Indies and trade operations in the United Kingdom. For more about Bizos Cavallo, visit the Bizos Cavallo Enterprises website (

To view this piece of content from, please give your consent at the top of this page.

Contact information

Chad Belisario
EVINS Communications

Chad Belisario
Bizos Cavallo Enterprises, LLC

Chad Belisario
V-Clean Technologies, Ltd

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ADM Accelerates Growth of Leading Global Alternative Protein Platform with Planned Acquisition of Sojaprotein26.7.2021 14:05:00 CEST | Press release

Global nutrition leader ADM (NYSE: ADM) announced today that it has reached an agreement to acquire Sojaprotein, a leading European provider of non-GMO soy ingredients. Established in 1977, Serbia-based Sojaprotein has sales into 65 countries, offering a wide array of non-GMO vegetable protein ingredients for an extensive list of European and global customers in the meat alternative, confectionary, protein bar, pharmaceutical, pet food, and animal feed segments. The company had more than $100 million in sales in 2020. “Thirty years ago, ADM invented the soy vegetable burger, giving rise to the plant-based protein segment. Today, alternative proteins represents one of our core growth platforms, and as this $10 billion global industry grows to $30 billion over the next decade, we are investing to expand our unparalleled capabilities,” said Leticia Gonçalves, ADM’s president of Global Foods. “The addition of Sojaprotein – the largest producer of plant-based protein in southern Europe – ad

ABB to Divest Mechanical Power Transmission Division (Dodge) to RBC Bearings for $2.9 Billion26.7.2021 13:30:00 CEST | Press release

ABB today announced it has signed a definitive agreement to divest its Mechanical Power Transmission division (Dodge) to RBC Bearings Incorporated (Nasdaq: ROLL), for $2.9 billion in cash. The transaction will create a leading manufacturer of highly engineered, performance-critical bearings and motion control components. The transaction is expected to be completed by the end of the year 2021, subject to customary closing conditions, including regulatory review. For more than 140 years, the Dodge business has been a leader in the design, production, and marketing of mounted bearings, enclosed gearing, and power transmission components. It offers one of the broadest portfolios of mechanical power transmission products in the market, selling to industries such as surface mining, aggregates & cement, warehousing and food & beverage. Dodge has roughly 1,500 employees worldwide and achieved revenues of approximately $600 million for the last twelve months ending June 30, 2021, of which more

CHMP grants positive opinion in the European Union for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba ® (delamanid) for the paediatric population weighing at least 10 kg with pulmonary multi-drug resistant tuberculosis26.7.2021 12:00:00 CEST | Press release

Otsuka Novel Products GmbH (ONPG), a subsidiary of Otsuka Pharmaceutical Co., Ltd., is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of Deltyba 25 mg dispersible tablets (delamanid) for use as part of an appropriate combination regimen for pulmonary MDR-TB in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. The current World Health Organization Global TB Report estimates that 1.2 million children (0-14 years of age) fell ill with TB in 2019.2 According to a scientific publication, every year approximately 25,000-32,000 children world-wide fall ill with MDR-TB. Of these, only a few are diagnosed and treated successfully and approximately 21% of children with MDR-TB are likely to die.1 New global targets set at the UN’s High Level Meeting on TB in 2018 inclu

First-of-Its-Kind “Pathways to Dairy Net Zero” Initiative to Raise Climate Ambition for the Global Dairy Sector26.7.2021 11:00:00 CEST | Press release

Afirst-of-its-kind Pathways to Dairy Net Zero initiative is being developed to accelerate climate change action throughout the global dairy sector. Announced today at the United Nations (UN) Food Systems Pre-Summit, the climate effort will be unlike any other in agriculture in terms of size, breadth, and scope. “The global dairy sector is creating this ground-breaking initiative to help speed climate action already underway, while continuing to provide livelihoods for a billion people and important nutrition for six billion people,” said Donald Moore, Executive Director at the Global Dairy Platform. A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop methodologies, tools and pathways that work for every dairy system. Pathways to Dairy Net Zero will officially launch during the UN Food Systems Summit in September and aims to generate commitments at the UN Climate C

Santen and IAPB Taking Action to Implement the First Ever UN General Assembly Resolution Recognizing the Link Between Eye Health and Sustainable Development26.7.2021 09:00:00 CEST | Press release

Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health. This comes after several months of collaboration with the IAPB, advocating for global action to improve access to basic eye health services. Santen is committed to reducing the loss of social and economic opportunities for people living with eye conditions. The new UN General Assembly resolution encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority. UN entities including UNICEF, UN-Women, UNDP, UNESCO, the International Labor Organization and the UN Road Safety Collaboration will work to promote and include eye health in their work. International financial institutions and donors will be urged to include eye health priorities in their funding programs. We

HKTDC Twin Jewellery Events Open in Hong Kong26.7.2021 08:52:00 CEST | Press release

The HKTDCHong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem & Pearl Show, opened on 25 July at the Hong Kong Convention and Exhibition Centre (HKCEC) and will run until 29 July. The twin shows are the first two physical trade fairs to be staged by the Hong Kong Trade Development Council (HKTDC), since the pandemic began and are being held in a hybrid format for the first time, with both physical and online exhibitions. The online show will run until 5 August to help global jewellers capture business opportunities as the pandemic continues. This press release features multimedia. View the full release here: The HKTDC Hong Kong International Jewellery Show and the HKTDC Hong Kong International Diamond, Gem & Pearl Show, organised by the Hong Kong Trade Development Council (HKTDC), take place on 25-29 July 2021 at the Hong Kong Convention and Exhibition Centre (HKCEC), helping jewellers capture bu

Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth26.7.2021 08:30:00 CEST | Press release

After nearly a decade of public-private collaboration, Ferring Pharmaceuticals today announces the first use of heat-stable carbetocin (Carbetocin Ferring) for the prevention of excessive bleeding after birth, known as postpartum haemorrhage (PPH). Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births. This press release features multimedia. View the full release here: Sarika – the first woman to receive heat-stable carbetocin, with her husband, newborn son and the first doctor to administer, Dr Yeshita V Pujar, Karnataka, India (Photo: Business Wire) This major maternal health milestone has been eagerly awaited since the publication of the CHAMPION (Carbetocin HAeMorrhage PreventION) trial results in 20182 - a study led by the World Health Organization (WHO) as part of a collaboration with MSD for Mothers* and